Skip to main navigation Skip to search Skip to main content

The Epigenetic Regulator SMCHD1 in Development and Disease

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

It has very recently become clear that the epigenetic modifier SMCHD1 has a role in two distinct disorders: facioscapulohumoral muscular dystrophy (FSHD) and Bosma arhinia and micropthalmia (BAMS). In the former there are heterozygous loss-of-function mutations, while both gain- and loss-of-function mutations have been proposed to underlie the latter. These findings have led to much interest in SMCHD1 and how it works at the molecular level. We summarise here current understanding of the mechanism of action of SMCHD1, its role in these diseases, and what has been learnt from study of mouse models null for Smchd1 in the decade since the discovery of SMCHD1.

Original languageEnglish
Pages (from-to)233-243
Number of pages11
JournalTrends in Genetics
Volume33
Issue number4
DOIs
Publication statusPublished - Apr 2017
Externally publishedYes

Keywords

  • Bosma arhinia and micropthalmia syndrome
  • epigenetic silencing
  • facioscapulohumoral muscular dystrophy
  • SMCHD1

Cite this